Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GKOS 
Glaukos Corp (GKOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: GKOS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $122.46
1 Year Target Price $122.46
| 9 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 72.97% | Avg. Invested days 59 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.63B USD | Price to earnings Ratio - | 1Y Target Price 122.46 |
Price to earnings Ratio - | 1Y Target Price 122.46 | ||
Volume (30-day avg) 15 | Beta 0.81 | 52 Weeks Range 77.10 - 163.71 | Updated Date 07/17/2025 |
52 Weeks Range 77.10 - 163.71 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.57% | Operating Margin (TTM) -19.39% |
Management Effectiveness
Return on Assets (TTM) -6.68% | Return on Equity (TTM) -20.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5760255403 | Price to Sales(TTM) 13.91 |
Enterprise Value 5760255403 | Price to Sales(TTM) 13.91 | ||
Enterprise Value to Revenue 14.24 | Enterprise Value to EBITDA -57.89 | Shares Outstanding 57140500 | Shares Floating 55192974 |
Shares Outstanding 57140500 | Shares Floating 55192974 | ||
Percent Insiders 3.33 | Percent Institutions 101.71 |
Upturn AI SWOT
Glaukos Corp
Company Overview
History and Background
Glaukos Corp. was founded in 1998 and is focused on the development and commercialization of novel therapies for glaucoma. It pioneered micro-invasive glaucoma surgery (MIGS) with the iStent.
Core Business Areas
- Glaucoma: Develops and sells micro-invasive glaucoma surgery (MIGS) devices, primarily the iStent family, designed to reduce intraocular pressure in glaucoma patients.
- Corneal Health: Focuses on developing and commercializing therapies for corneal health, including products for corneal disease and refractive correction.
Leadership and Structure
The leadership team includes Thomas W. Burns (Chairman, President and CEO). The company has a standard corporate structure with departments for R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- iStent inject W: A micro-invasive glaucoma surgery (MIGS) device implanted during cataract surgery to reduce intraocular pressure. The market share for MIGS is competitive, with Glaukos being a major player. Alcon and Ivantis are competitors. Revenue from iStent family is significant, comprising the majority of Glaukos' revenue.
- iPrime: Viscodelivery system of Omidentyne for reduction of IOP. The market share for MIGS is competitive, with Glaukos being a major player. Alcon and Ivantis are competitors.
Market Dynamics
Industry Overview
The glaucoma and corneal health market is growing due to the aging population and increasing prevalence of these conditions. Technological advancements in surgical and pharmaceutical treatments are driving market innovation.
Positioning
Glaukos is positioned as a leader in the MIGS market, with a focus on innovation and expanding its product portfolio to address a broader range of glaucoma and corneal diseases.
Total Addressable Market (TAM)
The TAM for glaucoma and corneal disease is estimated to be in the billions of dollars globally. Glaukos is well-positioned to capture a significant share through its existing products and pipeline.
Upturn SWOT Analysis
Strengths
- Pioneer and leader in the MIGS market
- Strong brand recognition in ophthalmology
- Extensive distribution network
- Innovative product pipeline
Weaknesses
- Reliance on a limited number of key products
- Intense competition in the glaucoma market
- Reimbursement challenges
- Dependence on regulatory approvals for new products
Opportunities
- Expanding into new geographic markets
- Developing new MIGS devices and therapies
- Acquiring complementary technologies and businesses
- Increasing adoption of MIGS procedures
Threats
- Increasing competition from established and emerging players
- Unfavorable changes in reimbursement policies
- Product liability claims
- Technological obsolescence
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- Ivantis (acquired by Alcon)
Competitive Landscape
Glaukos faces competition from larger, more established companies in the ophthalmic space. Glaukos' advantage lies in its focus on MIGS and its innovative product pipeline. Alcon and Johnson & Johnson have broader product portfolios and greater financial resources.
Major Acquisitions
DuraVision
- Year: 2023
- Acquisition Price (USD millions): 275
- Strategic Rationale: Expanded Glaukos' portfolio of products for corneal health, adding cross-linking and other corneal repair technologies.
Growth Trajectory and Initiatives
Historical Growth: Glaukos has experienced significant revenue growth driven by the adoption of iStent procedures.
Future Projections: Analysts project continued revenue growth for Glaukos, driven by new product launches and market expansion. Profitability is expected to improve over time.
Recent Initiatives: Recent initiatives include expanding the iStent portfolio, developing new therapies for corneal health, and pursuing strategic acquisitions.
Summary
Glaukos is a leading player in the MIGS market with a strong brand and innovative products. While the company faces competition and reimbursement challenges, it is well-positioned for continued growth in the expanding glaucoma and corneal health market. Its strategic acquisitions and focus on innovation are positive signs, but maintaining profitability amidst high R&D spending remains a key challenge. Investors should watch for continued market adoption of iStent and success of new product launches.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Research Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share and financial data are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Glaukos Corp
Exchange NYSE | Headquaters Aliso Viejo, CA, United States | ||
IPO Launch date 2015-06-25 | Chairman & CEO Mr. Thomas William Burns | ||
Sector Healthcare | Industry Medical Devices | Full time employees 995 | Website https://www.glaukos.com |
Full time employees 995 | Website https://www.glaukos.com | ||
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.